Valuation: Gilead Sciences, Inc.

Market Cap 169B 148B 136B 126B 237B 16,297B 242B 1,631B 642B 7,981B 636B 622B 27,476B P/E 2026 *
-49.1x
P/E 2027 * 17.3x
Enterprise Value 179B 156B 144B 133B 250B 17,208B 256B 1,722B 677B 8,428B 671B 656B 29,012B EV / Sales 2026 *
5.86x
EV / Sales 2027 * 5.22x
Free-Float
99.88%
Yield 2026 *
2.38%
Yield 2027 * 2.47%
1 day-0.32%
1 week+4.98%
Current month+7.88%
1 month+8.64%
3 months-0.98%
6 months+9.79%
Current year+11.04%
1 week 127.94
Extreme 127.935
140.61
1 month 122.43
Extreme 122.43
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
6/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
6/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+4.98%+25.27%+75.91% 169B
+0.85%-0.87%+54.72%+163.50% 1,043B
+1.16%-1.47%+55.36%+59.18% 602B
+1.08%+3.85%+34.60%+91.07% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-1.10%+1.34%+23.47%+61.63% 201B
-0.18%+3.91%+2.18%-29.96% 143B
-0.07%-0.11%+4.66%+35.44% 123B
Average +0.28%-0.83%+28.63%+55.20% 360.04B
Weighted average by Cap. +0.60%-1.83%+39.14%+83.24%

Financials

2026 *2027 *
Net sales 30.47B 26.63B 24.57B 22.65B 42.69B 2,934B 43.63B 294B 116B 1,437B 114B 112B 4,947B 32.4B 28.31B 26.13B 24.08B 45.39B 3,120B 46.4B 312B 123B 1,528B 122B 119B 5,260B
Net income -3.39B -2.96B -2.73B -2.52B -4.75B -327B -4.86B -32.68B -12.86B -160B -12.73B -12.46B -551B 9.76B 8.53B 7.87B 7.26B 13.68B 940B 13.98B 94.09B 37.01B 460B 36.66B 35.86B 1,585B
Net Debt 9.46B 8.27B 7.63B 7.03B 13.25B 911B 13.55B 91.18B 35.86B 446B 35.53B 34.75B 1,536B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-17 $135.54 -0.56% 2,997,033
26-07-16 $136.30 +3.49% 7,926,819
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
26-07-13 $131.40 +1.21% 5,131,594
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
136.30USD
Average target price
158.30USD
Spread / Average Target
+16.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock